passages: 4112
passages: document
passages: Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis . Although corticosteroid therapy might be clinically beneficial for bronchiectasis , very little is known of its effects on the inflammatory and infective markers in bronchiectasis . We have therefore performed a double-blind , placebo-controlled study to evaluate the effects of a 4-wk administration of inhaled fluticasone in bronchiectasis . Twenty-four patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo . At each visit , spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 ) were determined . There was a significant ( p < 0.05 ) decrease in sputum leukocyte density and IL-1beta , IL-8 , and LTB4 after fluticasone treatment . The fluticasone group had one and the placebo group three episodes of exacerbation . There were no significant changes in spirometry ( p > 0.05 ) or any reported adverse reactions in either group . The results of this study show that high-dose fluticasone is effective in reducing the sputum inflammatory indices in bronchiectasis . Large-scale and long-term studies are indicated to evaluate the effects of inhaled steroid therapy on the inflammatory components in bronchiectasis .
entities: 4113
entities: Intervention_Pharmacological
entities: fluticasone
entities: 4114
entities: Intervention_Control
entities: placebo-controlled
entities: 4115
entities: Intervention_Pharmacological
entities: fluticasone
entities: 4116
entities: Intervention_Pharmacological
entities: fluticasone
entities: 4117
entities: Intervention_Control
entities: placebo .
entities: 4118
entities: Intervention_Pharmacological
entities: fluticasone
entities: 4119
entities: Intervention_Pharmacological
entities: fluticasone
entities: 4120
entities: Intervention_Control
entities: placebo
entities: 4121
entities: Outcome_Physical
entities: sputum inflammatory indices
entities: 4122
entities: Outcome_Physical
entities: inflammatory and infective markers
entities: 4123
entities: Outcome_Physical
entities: spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities
entities: 4124
entities: Outcome_Physical
entities: concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha )
entities: 4125
entities: Outcome_Physical
entities: leukotriene B4 ( LTB4 )
entities: 4126
entities: Outcome_Physical
entities: sputum leukocyte density
entities: 4127
entities: Outcome_Physical
entities: IL-1beta , IL-8
entities: 4128
entities: Outcome_Physical
entities: LTB4
entities: 4129
entities: Outcome_Physical
entities: spirometry
entities: 4130
entities: Outcome_Adverse-effects
entities: adverse reactions
entities: 4131
entities: Outcome_Physical
entities: sputum inflammatory indices
entities: 4132
entities: Participant_Condition
entities: severe bronchiectasis .
entities: 4133
entities: Participant_Sample-size
entities: Twenty-four
entities: 4134
entities: Participant_Sample-size
entities: 12
entities: 4135
entities: Participant_Age
entities: mean age 51 yr
entities: 4136
entities: Participant_Condition
entities: bronchiectasis .